Trial · NCT00591825
fMRI Study Examining Effects of D-cycloserine in Specific Phobia
NCT00591825, Phase 2, Completed, University of Kansas Medical Center; results first posted 2017-06-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. fMRI Study Examining Effects of D-cycloserine in Specific Phobia. Trials, record NCT00591825. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00591825
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- fMRI Study Examining Effects of D-cycloserine in Specific Phobia
- NCT number
- NCT00591825
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 54 participants, actual
- Lead sponsor
- University of Kansas Medical Center
- Conditions
- Phobias
- Interventions
- D-cycloserine, Placebo
- First posted
- 2008-01-11
- Last updated
- 2017-06-05
- Results first posted
- 2017-06-05
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | fMRI Brain Activations During Symptom Provocation | 2 Weeks | Regions of interest (ROIs) were specified based on previous research and included amygdala, insula, dorsal anterior cingulate cortex (ACC), dorsolateral PFC (dlPFC), and hippocampus. Multiple regression analyses were used to examine differences in response between experimental conditions (spider versus butterfly images). For significant clusters of activation within ROIs, the average max percent signal change is reported. For other regions, the average max percent signal change is reported within a sphere centered at coordinates identified via previous research. |
| Secondary | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | 2 Weeks | This scale measures the learning and memory of functioning adults. Logical Memory I and II and Faces I and II subtests were administered to participants. The tasks measure verbal and visual memory, respectively. Scoring is based on the number of story details or faces correctly recalled during immediate (Logical Memory I, Faces I) and 30 minute delayed (Logical Memory II, Faces II) conditions. Total score ranges from 0-75 on Logical Memory I, 0-50 on Logical Memory II, 0-48 on Faces I, and 0-48 on Faces II. For all subtests, higher scores indicate better memory performance. |
| Secondary | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | 2 weeks | The RCFT assesses the a person's ability to use cues to retrieve information. The test measures visuospatial construction and memory. A person is asked to draw a figure. The figure is broken down into 18 elements. The score is based on their presence, completeness, and correct placement. Each element is scored from 0-2. The Copy, Immediate, and Delay results are scored on a 36 point scale. The higher the score, the better the person performed on the test with a 0 being the minimum and 36 being the maximum score. The organization score is scored according to whether the participant drew five cohesive units of the figure together, for a range of 0-6 and a higher score indicating better organizational performance. |
| Secondary | Cognitive Functioning Measured Using the Iowa Gambling Test | 2 weeks | This test measures a person's emotional decision making. Participants are presented with virtual decks of cards on a computer. Participants are told that each card they draw will "win" them game money. However, sometimes cards result in "losing" game money. The task includes 100 trials and the total score represents the number of cards drawn from "bad" decks as compared to "good" or safe decks. Thus, the score ranges from -100 to +100, with higher sores representing better performance. |
| Secondary | Cognitive Functioning Measured Using the Wisconsin Card Sorting Task | 2 weeks | The Wisconsin Card Sorting Task measures executive functioning and cognitive flexibility. The task uses a deck of 64 cards that the participant must sort according to specified rules. The test is stopped when when six sequences of 10 correct responses have been achieved, or after the deck has been completed twice, which provides a cumulative total of 128 trials. We report the number of errors on the task, which has a range of 0 -128, with a higher score representing worse performance. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | fMRI Brain Activations During Symptom Provocation | 2 Weeks | There were 54 enrolled in the study. 8 subjects were excluded from fMRI analyses: 1 for claustrophobia, 3 for scanner artifact, 1 because of motion \>3mm; 3 of paradigm-consistent motion which could not be corrected for. | percent signal change | MEAN |
| SECONDARY | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | 2 Weeks | units on a scale | MEAN | |
| SECONDARY | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | 2 weeks | units on a scale | MEAN | |
| SECONDARY | Cognitive Functioning Measured Using the Iowa Gambling Test | 2 weeks | units on a scale | MEAN | |
| SECONDARY | Cognitive Functioning Measured Using the Wisconsin Card Sorting Task | 2 weeks | Two subjects did not complete the test because they had previous exposure to the test. | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group112
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| fMRI Brain Activations During Symptom Provocation | DCS Phobic | Left Insula Spider | .200 | Standard Deviation .182 | percent signal change |
| fMRI Brain Activations During Symptom Provocation | DCS Control | Left Insula Spider | .157 | Standard Deviation .373 | percent signal change |
| fMRI Brain Activations During Symptom Provocation | Placebo Phobic | Left Insula Spider | -.013 | Standard Deviation .167 | percent signal change |
| fMRI Brain Activations During Symptom Provocation | Placebo Control | Left Insula Spider | .036 | Standard Deviation .095 | percent signal change |
| fMRI Brain Activations During Symptom Provocation | DCS Phobic | Left Insula Butterfly | .012 | Standard Deviation .139 | percent signal change |
| fMRI Brain Activations During Symptom Provocation | DCS Control | Left Insula Butterfly | .021 | Standard Deviation .376 | percent signal change |
| fMRI Brain Activations During Symptom Provocation | Placebo Phobic | Left Insula Butterfly | .092 | Standard Deviation .162 | percent signal change |
| fMRI Brain Activations During Symptom Provocation | Placebo Control | Left Insula Butterfly | .079 | Standard Deviation .147 | percent signal change |
| fMRI Brain Activations During Symptom Provocation | DCS Phobic | Right Insula Spider | .107 | Standard Deviation .190 | percent signal change |
| fMRI Brain Activations During Symptom Provocation | DCS Control | Right Insula Spider | .174 | Standard Deviation .287 | percent signal change |
1 to 10 of 112Source ClinicalTrials.gov
See all 112 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Non-Phobic Control - Placebo | 14 | |
| Overall Study | STARTED | Non-Phobic Control - DCS | 13 | |
| Overall Study | STARTED | Spider-phobic Placebo | 13 | |
| Overall Study | STARTED | Spider-phobic DCS | 14 | |
| Overall Study | COMPLETED | Non-Phobic Control - Placebo | 14 | |
| Overall Study | COMPLETED | Non-Phobic Control - DCS | 13 | |
| Overall Study | COMPLETED | Spider-phobic Placebo | 13 | |
| Overall Study | COMPLETED | Spider-phobic DCS | 14 | |
| Overall Study | NOT COMPLETED | Non-Phobic Control - Placebo | 0 | |
| Overall Study | NOT COMPLETED | Non-Phobic Control - DCS | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Non-Phobic Control - Placebo | 0 | 14 |
| Total, all-cause mortality | Non-Phobic Control - DCS | 0 | 13 |
| Total, all-cause mortality | Spider-phobic Placebo | 0 | 13 |
| Total, all-cause mortality | Spider-phobic DCS | 0 | 13 |
| Total, other adverse events | Non-Phobic Control - Placebo | 0 | 14 |
| Total, other adverse events | Non-Phobic Control - DCS | 0 | 13 |
| Total, other adverse events | Spider-phobic Placebo | 0 | 13 |
| Total, other adverse events | Spider-phobic DCS | 0 | 14 |
| Total, serious adverse events | Non-Phobic Control - Placebo | 0 | 14 |
| Total, serious adverse events | Non-Phobic Control - DCS | 0 | 13 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Card Sorting Test (Berg) | Secondary outcome | ConductCognition |
| Complex Figure Copy and Recall | Secondary outcome | ConductCognition |
| Iowa Gambling Lite | Secondary outcome | ConductCognition |
| Short Story Recall | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00591825
GET https://conductscience.org/api/trials/v1/NCT00591825/results?page=2